Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

An Exploration of the Associations of Alcohol-Related Social Media Use and Message Interpretation Outcomes to Problem Drinking Among College Students.

Hoffman EW, Austin EW, Pinkleton BE, Austin BW.

Health Commun. 2017 Jul;32(7):864-871. doi: 10.1080/10410236.2016.1195677. Epub 2016 Jul 15.

PMID:
27421038
2.

A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.

Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW.

Gynecol Oncol. 2015 Aug;138(2):272-7. doi: 10.1016/j.ygyno.2015.05.023. Epub 2015 May 27.

PMID:
26026738
3.

Exploring college students' use of general and alcohol-related social media and their associations with alcohol-related behaviors.

Hoffman EW, Pinkleton BE, Weintraub Austin E, Reyes-Velázquez W.

J Am Coll Health. 2014;62(5):328-35. doi: 10.1080/07448481.2014.902837.

PMID:
24635485
4.

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S.

Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2.

5.

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD.

Invest New Drugs. 2013 Apr;31(2):425-34. doi: 10.1007/s10637-012-9862-2. Epub 2012 Aug 5.

6.

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J.

Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23.

PMID:
21698545
7.

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.

Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E.

Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29.

8.

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.

Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J.

Clin Cancer Res. 2009 Mar 15;15(6):2166-73. doi: 10.1158/1078-0432.CCR-08-2484. Epub 2009 Mar 10.

9.

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.

Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E.

Int J Cancer. 2008 Nov 15;123(10):2362-9. doi: 10.1002/ijc.23810.

10.

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.

Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N.

J Immunol. 2008 Jul 1;181(1):776-84.

11.

Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.

Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K.

Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1.

PMID:
18311489
12.

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.

Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5. doi: 10.1073/pnas.0707140104. Epub 2008 Jan 23.

13.

Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel.

Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, Shiraishi T, Akiyoshi K, Scott AM, Murphy R, Hoffman EW, Old LJ, Katayama N, Shiku H.

Cancer Sci. 2008 Mar;99(3):601-7. Epub 2007 Dec 15.

14.

A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.

Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:14.

15.

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.

16.

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. Epub 2007 Jul 25.

17.

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ.

Clin Cancer Res. 2007 Jun 1;13(11):3286-92.

18.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

19.

HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.

Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M, Nishikawa M, Sunamoto J, Akiyoshi K, Kanematsu T, Scott AM, Murphy R, Hoffman EW, Old LJ, Shiku H.

Clin Cancer Res. 2006 Dec 15;12(24):7397-405.

20.

A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.

Sakamoto J, Oriuchi N, Mochiki E, Asao T, Scott AM, Hoffman EW, Jungbluth AA, Matsui T, Lee FT, Papenfuss A, Kuwano H, Takahashi T, Endo K, Old LJ.

Cancer Sci. 2006 Nov;97(11):1248-54.

21.

Application of a five-step message development model for food safety education materials targeting people with HIV/AIDS.

Hoffman EW, Bergmann V, Shultz JA, Kendall P, Medeiros LC, Hillers VN.

J Am Diet Assoc. 2005 Oct;105(10):1597-604.

PMID:
16183361
22.

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.

Clin Cancer Res. 2005 Jul 1;11(13):4818-26.

23.

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

Murphy R, Green S, Ritter G, Cohen L, Ryan D, Woods W, Rubira M, Cebon J, Davis ID, Sjolander A, Kypridis A, Kalnins H, McNamara M, Moloney MB, Ackland J, Cartwright G, Rood J, Dumsday G, Healey K, Maher D, Maraskovsky E, Chen YT, Hoffman EW, Old LJ, Scott AM.

Prep Biochem Biotechnol. 2005;35(2):119-34.

PMID:
15881594
24.

Translation of cancer immunotherapies.

Skipper J, Hoffman EW, O'Donnell-Tormey J, Old LJ.

Nat Med. 2004 Nov;10(11):1154-5; author reply 1155. No abstract available.

PMID:
15516901
25.

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702. Epub 2004 Jul 13. Erratum in: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9734.

26.

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S.

J Immunol. 2004 Mar 1;172(5):3289-96.

27.

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.

Clin Cancer Res. 2003 May;9(5):1639-47.

28.

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ.

J Clin Oncol. 2001 Oct 1;19(19):3976-87.

PMID:
11579119
29.

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.

Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G.

Ann Intern Med. 1994 Oct 1;121(7):492-501.

PMID:
7520676
30.

A prospective evaluation of therapeutic drug monitoring.

Bussey HI, Hoffman EW.

Ther Drug Monit. 1983;5(3):245-8.

PMID:
6636250
31.

Basics of cardiovascular hemodynamic monitoring.

Hoffman EW.

Drug Intell Clin Pharm. 1982 Sep;16(9):657-64. Review.

PMID:
6751753
32.

Phenytoin-induced interstitial nephritis.

Hoffman EW.

South Med J. 1981 Sep;74(9):1160-1. No abstract available.

PMID:
7280771

Supplemental Content

Loading ...
Support Center